Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley bought 40,000 shares of the company's stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $0.60 per share, for a total transaction of $24,000.00. Following the completion of the transaction, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Lineage Cell Therapeutics Trading Down 16.0 %
Shares of NYSEAMERICAN LCTX opened at $0.50 on Friday. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $1.61.
Analyst Ratings Changes
Separately, Craig Hallum began coverage on Lineage Cell Therapeutics in a research report on Tuesday, August 20th. They set a "buy" rating and a $4.00 price target on the stock.
Check Out Our Latest Research Report on Lineage Cell Therapeutics
Institutional Investors Weigh In On Lineage Cell Therapeutics
Could This Tiny Device Help You Make an Extra $30k a Year?
From Brownstone Research | Ad
I believe it’s going to power Elon Musk’s next AI revolution…
A revolution he believes will be worth more than $9 trillion.
That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Click here to see the details because I believe a lot of people will get rich.
Several institutional investors have recently bought and sold shares of the company. Raffles Associates LP boosted its stake in Lineage Cell Therapeutics by 35.8% during the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company's stock worth $4,346,000 after purchasing an additional 1,147,800 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Lineage Cell Therapeutics by 35.7% in the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after buying an additional 114,762 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock worth $132,000 after buying an additional 17,411 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company's stock worth $239,000 after acquiring an additional 70,418 shares during the last quarter. Finally, Comerica Bank grew its stake in Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company's stock valued at $370,000 after acquiring an additional 250,000 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.
Lineage Cell Therapeutics Company Profile
(
Get Free Report)
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
